Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.62 |
| ▸ | MITF | O75030 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.58 |
| ▸ | CFTR | P13569 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12008451 | 0.85 | MAPT (0.82) | MEN1KMT2AMAPTNCOA3AKR1B1 | |
| SCHEMBL5281534 | 0.85 | MAPK1 (0.72) | MEN1KMT2AMAPTNCOA3MITF | |
| SCHEMBL5281537 | 0.85 | MAPK1 (0.72) | MEN1KMT2AMAPTNCOA3MITF | |
| SCHEMBL5281527 | 0.85 | MAPK1 (0.72) | MEN1KMT2AMAPTNCOA3MITF | |
| SCHEMBL19999085 | 0.82 | MAPT (0.77) | MEN1KMT2AMAPTAKR1B1ALDH1A1 | |
| SCHEMBL6884124 | 0.80 | BCL2L2 (0.66) | MEN1KMT2AMAPTAKR1B1ALDH1A1 | |
| SCHEMBL6884127 | 0.80 | BCL2L2 (0.66) | MEN1KMT2AMAPTAKR1B1ALDH1A1 | |
| SCHEMBL18102932 | 0.80 | CISD1 (0.76) | MEN1KMT2AAKR1B1CISD1MAOB | |
| SCHEMBL24217825 | 0.79 | CISD1 (0.71) | MEN1KMT2AMAPTCISD1MAOB | |
| SCHEMBL12008452 | 0.78 | AKR1B1 (0.80) | MEN1KMT2AMAPTNCOA3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| WO-2016154255-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | UNIVERSITY OF MIAMI (US) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | MEN1 846/4885KMT2A 470/4885MAPT 3938/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | MEN1 846/4885KMT2A 470/4885MAPT 3938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.